Business Wire

QUECTEL-WIRELESS

9.4.2024 09:01:27 CEST | Business Wire | Press release

Share
Quectel Broadens RedCap Offering With Commercial Availability of RG255C-GL RedCap 5G Module

Embedded World--Quectel Wireless Solutions, a global IoT solutions provider, is delighted to announce the commercial availability of the RG255C-GL 5G RedCap Sub-6 GHz LGA module, delivering comprehensive 5G and 4G coverage across the globe. Based on Qualcomm Technologies, Inc.'s Snapdragon® X35 baseband chipset, the RG255C-GL offers exceptional wireless performance, empowering seamless low-latency 5G communication and advanced features including 5G LAN, URLLC, and network slicing.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240409408432/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Quectel broadens RedCap offering with commercial availability of RG255C-GL RedCap 5G module (Photo: Business Wire)

The RG255C-GL, conforming to 3GPP Release 17 standards, features a compact LGA form factor measuring 32.0mm x 29.0mm x 2.4mm. With impressive data rates of 223 Mbps downlink and 123 Mbps uplink, it is tailored for applications such as CPEs, MiFi, Router, Gateway, or Industrial PDA. Additionally, this module supports LTE Cat 4 and 5G Sub-6 SA mode, ensuring compatibility with Rel-15 and Rel-16 networks for seamless integration and versatile deployment.

Furthermore, the module is compatible with Quectel 4G module EG2x series modules with smaller sizes, which can meet customers’ different application demands for medium speed, large capacity, low latency, and high reliability, making it ideal for customers to design in to current device applications.

"Having the RG255C-GL 5G RedCap module commercially available offers our customers access to the benefits of 5G without the accompanying expense and power consumption," commented Norbert Muhrer, President and CSO, Quectel Wireless Solutions. "This technology paves the way for diverse IoT applications requiring worldwide 4G and 5G coverage with ultra-reliable low latency communications (URLLC) and network slicing."

RG255C-GL is designed for the global market and covers nearly all the mainstream carriers worldwide. The module features Qualcomm® IZat™️ location technology, offering GPS, GLONASS, BDS, and Galileo positioning functionalities. With its integrated GNSS receiver, customers can streamline their product design while enjoying enhanced positioning capabilities with greater speed and accuracy.

A wide range of interfaces including USB 2.0, PCle 2.0, PCM, UART, SGMII and SPI alongside a large number of drivers means that this module is ideal for a wide range of RedCap applications.

Quectel prioritizes security throughout the development of its IoT modules. Starting from product architecture to firmware/software development, Quectel integrates top industry practices and standards to address potential vulnerabilities. They collaborate with third-party independent test houses to mitigate risks and implement security measures such as generating SBOMs and VEX files, as well as conducting firmware binary analysis throughout the entire software development lifecycle.

The RG255C-GL RedCap module will be available alongside a series of antennas, providing developers with the ability to purchase module and antennas at the same time, reducing cost and time to market.

Attendees to Embedded World will be able to find out more about the RG255C-GL 5G RedCap module on the Quectel stand at booth number 3-318.

About Quectel

Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,900 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules as well as antennas and services.

With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.

For more information, please visit: www.quectel.com, LinkedIn, Facebook, and X.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240409408432/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye